ケルニクテルス治療の世界市場レポート 2025年

ケルニクテルス治療の市場規模は、今後数年間で安定した成長が見込まれます。2029年には33億7,000万米ドルに成長し、CAGRは2.4%となります。予測期間の成長は、継続的な医学教育プログラム、世界の保健政策とイニシアチブ、患者擁護と支援団体、小児科研究の国際協力、新生児保健のための政府助成金などに起因すると考えられます。予測期間の主な動向には、新生児黄疸モニタリング技術の進歩、機能強化された光線療法機器の導入、ビリルビン減少薬の開発、在宅光線療法ソリューションの重視、ビリルビンノモグラムとガイドラインの導入、遠隔モニタリングのためのテレヘルスの統合などがあります。

新生児黄疸の有病率の上昇は、ケルニクテルス治療市場の成長を促進すると予想されます。新生児黄疸は、一般的に新生児で観察され、皮膚や目の黄変を特徴とする良性の疾患です。ケルニクテルス治療は新生児黄疸の場合、症状の管理と支持療法を提供するために適用されることが多いです。この治療では、赤ちゃんの血液をビリルビン濃度の低い血液と交換し、子どもの生活の質を高める。例えば、2023年10月、米国に拠点を置く国立医学図書館は、正期産児の約60％、早産児の約80％が生後1週間以内に黄疸を発症し、母乳栄養児の約10％が1ヵ月時点でも黄疸を示すと報告しています。このように、新生児黄疸の広範な発生は、ケルニクテルス治療市場を押し上げると予想されます。

ヘルスケア支出の増加がケルニクテルス治療市場の成長に拍車をかけています。この種の支出とは、ヘルスケアサービス、プログラム、インフラの拡大や強化に伴うコスト上昇に対処するために、ヘルスケア部門で行われる追加投資のことを指します。このような支出は、罹患した乳幼児や小児の治療の質とアクセシビリティを向上させ、治療結果の改善と生活の質の向上につながることで、ケルニクテルス治療に大きな影響を与えます。例えば、2023年11月、カナダ医療情報研究所（Canadian Institute for Health Information）は、2023年のカナダにおける総医療費は3,440億米ドル（1人当たり8,740ドル）に達する見込みであり、前年の伸び率1.5％から2.8％増加すると報告し、医療投資の力強い復活を示唆しました。その結果、ヘルスケア支出の増加がケルニクテルス治療市場成長の原動力となっています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- 金利、インフレ、地政学、コロナ、回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界ケルニクテルス治療PESTEL分析（政治、社会、技術、環境、法的要因、促進要因、抑制要因）
• 最終用途産業の分析
• 世界のケルニクテルス治療市場：成長率分析
• 世界のケルニクテルス治療市場の実績：規模と成長, 2019-2024
• 世界のケルニクテルス治療市場の予測：規模と成長, 2024-2029, 2034F
• 世界ケルニクテルス治療総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界のケルニクテルス治療市場治療別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 光線療法
• 静脈内免疫グロブリン（IVIG）
• 輸血
• 薬
• その他の治療法
• 世界のケルニクテルス治療市場症状別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 黄疸
• 異常な眼球運動
• 嘔吐
• 熱
• 栄養不良
• 無呼吸
• イライラ
• 発作
• 眠気
• その他の症状
• 世界のケルニクテルス治療市場投与量別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 注射
• ソリューション
• その他の投与量
• 世界のケルニクテルス治療市場：エンドユーザー別、実績と予測, 2019-2024, 2024-2029F, 2034F
• クリニック
• 病院
• その他のエンドユーザー
• 世界のケルニクテルス治療市場、光線療法の種類別のサブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 従来の光線療法
• ファイバーオプティック光線療法
• LED光線療法
• 世界のケルニクテルス治療市場、静脈内免疫グロブリン（IVIG）のサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 標準的なIVIG療法
• 高用量IVIG療法
• 世界のケルニクテルス治療市場、輸血の種類別のサブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 交換輸血
• 単純輸血
• 世界のケルニクテルス治療市場、医薬品のサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• ビリルビン低下剤
• 抗酸化物質
• 神経保護剤
• 世界のケルニクテルス治療市場、その他の治療法のサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 支持療法
• 栄養サポート
• 補助療法

第7章 地域別・国別分析

• 世界のケルニクテルス治療市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界のケルニクテルス治療市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• ケルニクテルス治療市場：競合情勢
• ケルニクテルス治療市場：企業プロファイル
  • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • F. Hoffmann-La Roche Ltd Overview, Products and Services, Strategy and Financial Analysis
  • Merck and Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Bayer AG Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Novartis AG
• AstraZeneca plc.
• Abbott Laboratories
• Sanofi SA
• GlaxoSmithKline plc
• Takeda Pharmaceutical Company Limited
• Johnson and Johnson Private Limited
• Baxter International Inc.
• Grifols S.A
• Sun Pharmaceutical Industries Ltd.
• Dr. Reddy's Laboratories Ltd.
• Alembic Pharmaceuticals Limited
• Lupin Pharmaceuticals Inc.
• CSL Limited
• Glenmark Pharmaceuticals Ltd.

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• ケルニクテルス治療市場2029：新たな機会を提供する国
• ケルニクテルス治療市場2029：新たな機会を提供するセグメント
• ケルニクテルス治療市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Kernicterus is an infrequent neurological condition that may manifest in newborns experiencing severe jaundice, marked by elevated levels of bilirubin in the bloodstream. Treatment for kernicterus encompasses medical interventions, therapies, and supportive care, primarily administered to infants and children, with the goal of addressing symptoms, complications, and long-term effects, ultimately enhancing the affected individuals' quality of life.

The primary modalities for treating kernicterus include phototherapy, intravenous immunoglobulins (IVIG), blood transfusion, medication, and other supportive measures. Phototherapy involves the application of light, typically specialized lights or lamps, as a medical intervention. This method is employed to address a range of symptoms associated with kernicterus, such as jaundice, unusual eye movements, vomiting, fever, poor feeding, apnea, irritability, seizures, sleepiness, and others. Dosage administration may take various forms, including injections, solutions, and other delivery methods. The end users of these treatments include clinics, hospitals, and other healthcare facilities.

The kernicterus treatment market research report is one of a series of new reports from The Business Research Company that provides kernicterus treatment market statistics, including kernicterus treatment industry global market size, regional shares, competitors with a kernicterus treatment market share, detailed kernicterus treatment market segments, market trends and opportunities, and any further data you may need to thrive in the kernicterus treatment industry. This kernicterus treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The kernicterus treatment market size has grown steadily in recent years. It will grow from $2.98 billion in 2024 to $3.06 billion in 2025 at a compound annual growth rate (CAGR) of 3.0%. The growth in the historic period can be attributed to improvements in neonatal care practices, increased awareness among healthcare professionals, government initiatives for maternal and child health, research funding and clinical trials, collaborations in medical research.

The kernicterus treatment market size is expected to see steady growth in the next few years. It will grow to $3.37 billion in 2029 at a compound annual growth rate (CAGR) of 2.4%. The growth in the forecast period can be attributed to continuous medical education programs, global health policies and initiatives, patient advocacy and support groups, international collaboration in pediatric research, government funding for neonatal health. Major trends in the forecast period include advancements in neonatal jaundice monitoring technologies, introduction of phototherapy devices with enhanced features, development of bilirubin-reducing medications, focus on home-based phototherapy solutions, implementation of bilirubin nomograms and guidelines, integration of telehealth for remote monitoring.

The rising prevalence of neonatal jaundice is expected to drive the growth of the kernicterus treatment market. Neonatal jaundice, commonly observed in newborns, is typically a benign condition marked by yellowing of the skin and eyes. Kernicterus treatment is often applied in cases of neonatal jaundice to manage symptoms and provide supportive care. This treatment involves exchanging the baby's blood with blood containing lower bilirubin levels, which enhances the child's quality of life. For instance, in October 2023, the U.S.-based National Library of Medicine reported that approximately 60% of term infants and 80% of preterm infants develop jaundice within their first week, with about 10% of breastfed infants still showing jaundice at one month. Thus, the widespread occurrence of neonatal jaundice is anticipated to boost the kernicterus treatment market.

Increasing healthcare spending is fueling the growth of the kernicterus treatment market. This type of spending refers to additional investments made in the healthcare sector to address the rising costs associated with expanding or enhancing healthcare services, programs, or infrastructure. Such spending significantly impacts kernicterus treatment by improving the quality and accessibility of care for affected infants and children, leading to better treatment outcomes and an improved quality of life. For example, in November 2023, the Canadian Institute for Health Information reported that total healthcare spending in Canada is expected to reach $344 billion in 2023, or $8,740 per person, marking a 2.8% increase from the prior year's 1.5% growth rate, signaling a strong resurgence in healthcare investment. Consequently, increased healthcare spending is a driving force behind the growth of the kernicterus treatment market.

Key organizations in the cornea treatment market are increasingly focusing on partnerships to expand their reach and strengthen their competitive position. For example, in July 2024, the UCL Department of Medical Physics and Biomedical Engineering, a UK-based institution known for its contributions to medical physics and biomedical engineering research and education, collaborated with UCL Hospitals, a UK-based healthcare provider, to launch NeoSCB. This smartphone application detects severe jaundice in newborns by analyzing images of the sclera (the white part of the eye), offering a non-invasive screening method. The app is particularly valuable in resource-limited settings where traditional jaundice screening devices are expensive. By measuring the yellowness of the sclera, the app correlates this data with bilirubin levels in the blood, achieving a high accuracy rate by successfully identifying 74 out of 79 infants with severe jaundice. Its performance is comparable to conventional methods, such as transcutaneous bilirubinometers, which measure bilirubin through the skin.

In March 2024, Intermountain Health, a US-based nonprofit healthcare system, formed a partnership with Picterus AS to enhance early jaundice detection for newborns. This collaboration aims to improve health outcomes by offering a non-invasive and accessible screening method. Picterus AS, a healthcare technology company based in Norway, specializes in developing technology for screening and monitoring neonatal jaundice.

Major companies operating in the kernicterus treatment market report are Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck and Co. Inc., AbbVie Inc., Bayer AG, Novartis AG, AstraZeneca plc., Abbott Laboratories, Sanofi SA, GlaxoSmithKline PLC, Takeda Pharmaceutical Company Limited, Johnson and Johnson Private Limited, Baxter International Inc., Grifols S.A, Sun Pharmaceutical Industries Ltd., Dr. Reddy's Laboratories Ltd., Alembic Pharmaceuticals Limited, Lupin Pharmaceuticals Inc., CSL Limited, Glenmark Pharmaceuticals Ltd., Cipla Inc., Torrent Pharmaceuticals Ltd., Octapharma Brasil Ltda, Kedrion S.p.A, Biotest AG, Wockhardt Ltd., Mylan N.V., Cadila Healthcare Ltd., Teva Pharmaceutical Industries Ltd., China Biologic Products Holdings Inc.

North America was the largest region in the kernicterus treatment market in 2024. The regions covered in the kernicterus treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the kernicterus treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The kernicterus treatment market consists of revenues earned by entities by provide kernicterus treatment services such as diagnostic tests, neurological management, medical evaluation and monitoring and exchange transfusion services. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Kernicterus Treatment Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on kernicterus treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for kernicterus treatment ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The kernicterus treatment market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Treatment: Phototherapy; Intravenous Immunoglobulins (IVIG); Blood Transfusion; Medication; Other Treatments
• 2) By Symptoms: Jaundice; Unusual Eye Movements; Vomiting; Fever; Poor Feeding; Apnoea; Irritability; Seizures; Sleepiness; Other Symptoms
• 3) By Dosage: Injection; Solution; Other Dosages
• 4) By End-Users: Clinic; Hospital; Other End-Users
• Subsegments:
• 1) By Phototherapy: Conventional Phototherapy; Fiberoptic Phototherapy; LED Phototherapy
• 2) By Intravenous Immunoglobulins (IVIG): Standard IVIG Therapy; High-Dose IVIG Therapy
• 3) By Blood Transfusion: Exchange Transfusion; Simple Transfusion
• 4) By Medication: Bilirubin-Lowering Agents; Antioxidants; Neuroprotective Agents
• 5) By Other Treatments: Supportive Care; Nutritional Support; Adjunct Therapies
• Companies Mentioned: Pfizer Inc.; F. Hoffmann-La Roche Ltd; Merck and Co. Inc.; AbbVie Inc.; Bayer AG
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Kernicterus Treatment Market Characteristics

3. Kernicterus Treatment Market Trends And Strategies

4. Kernicterus Treatment Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Covid And Recovery On The Market

5. Global Kernicterus Treatment Growth Analysis And Strategic Analysis Framework

• 5.1. Global Kernicterus Treatment PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Kernicterus Treatment Market Growth Rate Analysis
• 5.4. Global Kernicterus Treatment Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Kernicterus Treatment Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Kernicterus Treatment Total Addressable Market (TAM)

6. Kernicterus Treatment Market Segmentation

• 6.1. Global Kernicterus Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Phototherapy
• Intravenous Immunoglobulins (IVIG)
• Blood Transfusion
• Medication
• Other Treatments
• 6.2. Global Kernicterus Treatment Market, Segmentation By Symptoms, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Jaundice
• Unusual Eye Movements
• Vomiting
• Fever
• Poor Feeding
• Apnoea
• Irritability
• Seizures
• Sleepiness
• Other Symptoms
• 6.3. Global Kernicterus Treatment Market, Segmentation By Dosage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Injection
• Solution
• Other Dosages
• 6.4. Global Kernicterus Treatment Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Clinic
• Hospital
• Other End-Users
• 6.5. Global Kernicterus Treatment Market, Sub-Segmentation Of Phototherapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Conventional Phototherapy
• Fiberoptic Phototherapy
• LED Phototherapy
• 6.6. Global Kernicterus Treatment Market, Sub-Segmentation Of Intravenous Immunoglobulins (IVIG), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Standard IVIG Therapy
• High-Dose IVIG Therapy
• 6.7. Global Kernicterus Treatment Market, Sub-Segmentation Of Blood Transfusion, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Exchange Transfusion
• Simple Transfusion
• 6.8. Global Kernicterus Treatment Market, Sub-Segmentation Of Medication, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Bilirubin-Lowering Agents
• Antioxidants
• Neuroprotective Agents
• 6.9. Global Kernicterus Treatment Market, Sub-Segmentation Of Other Treatments, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Supportive Care
• Nutritional Support
• Adjunct Therapies

7. Kernicterus Treatment Market Regional And Country Analysis

• 7.1. Global Kernicterus Treatment Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Kernicterus Treatment Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Kernicterus Treatment Market

• 8.1. Asia-Pacific Kernicterus Treatment Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Kernicterus Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Kernicterus Treatment Market, Segmentation By Symptoms, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Kernicterus Treatment Market, Segmentation By Dosage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Kernicterus Treatment Market

• 9.1. China Kernicterus Treatment Market Overview
• 9.2. China Kernicterus Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Kernicterus Treatment Market, Segmentation By Symptoms, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Kernicterus Treatment Market, Segmentation By Dosage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Kernicterus Treatment Market

• 10.1. India Kernicterus Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Kernicterus Treatment Market, Segmentation By Symptoms, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Kernicterus Treatment Market, Segmentation By Dosage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Kernicterus Treatment Market

• 11.1. Japan Kernicterus Treatment Market Overview
• 11.2. Japan Kernicterus Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Kernicterus Treatment Market, Segmentation By Symptoms, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Kernicterus Treatment Market, Segmentation By Dosage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Kernicterus Treatment Market

• 12.1. Australia Kernicterus Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Kernicterus Treatment Market, Segmentation By Symptoms, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Kernicterus Treatment Market, Segmentation By Dosage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Kernicterus Treatment Market

• 13.1. Indonesia Kernicterus Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Kernicterus Treatment Market, Segmentation By Symptoms, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Kernicterus Treatment Market, Segmentation By Dosage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Kernicterus Treatment Market

• 14.1. South Korea Kernicterus Treatment Market Overview
• 14.2. South Korea Kernicterus Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Kernicterus Treatment Market, Segmentation By Symptoms, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Kernicterus Treatment Market, Segmentation By Dosage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Kernicterus Treatment Market

• 15.1. Western Europe Kernicterus Treatment Market Overview
• 15.2. Western Europe Kernicterus Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Kernicterus Treatment Market, Segmentation By Symptoms, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Kernicterus Treatment Market, Segmentation By Dosage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Kernicterus Treatment Market

• 16.1. UK Kernicterus Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Kernicterus Treatment Market, Segmentation By Symptoms, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Kernicterus Treatment Market, Segmentation By Dosage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Kernicterus Treatment Market

• 17.1. Germany Kernicterus Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Kernicterus Treatment Market, Segmentation By Symptoms, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Kernicterus Treatment Market, Segmentation By Dosage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Kernicterus Treatment Market

• 18.1. France Kernicterus Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Kernicterus Treatment Market, Segmentation By Symptoms, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Kernicterus Treatment Market, Segmentation By Dosage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Kernicterus Treatment Market

• 19.1. Italy Kernicterus Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Kernicterus Treatment Market, Segmentation By Symptoms, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Kernicterus Treatment Market, Segmentation By Dosage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Kernicterus Treatment Market

• 20.1. Spain Kernicterus Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Kernicterus Treatment Market, Segmentation By Symptoms, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Kernicterus Treatment Market, Segmentation By Dosage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Kernicterus Treatment Market

• 21.1. Eastern Europe Kernicterus Treatment Market Overview
• 21.2. Eastern Europe Kernicterus Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Kernicterus Treatment Market, Segmentation By Symptoms, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Kernicterus Treatment Market, Segmentation By Dosage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Kernicterus Treatment Market

• 22.1. Russia Kernicterus Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Kernicterus Treatment Market, Segmentation By Symptoms, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Kernicterus Treatment Market, Segmentation By Dosage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Kernicterus Treatment Market

• 23.1. North America Kernicterus Treatment Market Overview
• 23.2. North America Kernicterus Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Kernicterus Treatment Market, Segmentation By Symptoms, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Kernicterus Treatment Market, Segmentation By Dosage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Kernicterus Treatment Market

• 24.1. USA Kernicterus Treatment Market Overview
• 24.2. USA Kernicterus Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Kernicterus Treatment Market, Segmentation By Symptoms, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Kernicterus Treatment Market, Segmentation By Dosage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Kernicterus Treatment Market

• 25.1. Canada Kernicterus Treatment Market Overview
• 25.2. Canada Kernicterus Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Kernicterus Treatment Market, Segmentation By Symptoms, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Kernicterus Treatment Market, Segmentation By Dosage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Kernicterus Treatment Market

• 26.1. South America Kernicterus Treatment Market Overview
• 26.2. South America Kernicterus Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Kernicterus Treatment Market, Segmentation By Symptoms, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Kernicterus Treatment Market, Segmentation By Dosage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Kernicterus Treatment Market

• 27.1. Brazil Kernicterus Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Kernicterus Treatment Market, Segmentation By Symptoms, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Kernicterus Treatment Market, Segmentation By Dosage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Kernicterus Treatment Market

• 28.1. Middle East Kernicterus Treatment Market Overview
• 28.2. Middle East Kernicterus Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Kernicterus Treatment Market, Segmentation By Symptoms, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Kernicterus Treatment Market, Segmentation By Dosage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Kernicterus Treatment Market

• 29.1. Africa Kernicterus Treatment Market Overview
• 29.2. Africa Kernicterus Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Kernicterus Treatment Market, Segmentation By Symptoms, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Kernicterus Treatment Market, Segmentation By Dosage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Kernicterus Treatment Market Competitive Landscape And Company Profiles

• 30.1. Kernicterus Treatment Market Competitive Landscape
• 30.2. Kernicterus Treatment Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. F. Hoffmann-La Roche Ltd Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Merck and Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Bayer AG Overview, Products and Services, Strategy and Financial Analysis

31. Kernicterus Treatment Market Other Major And Innovative Companies

• 31.1. Novartis AG
• 31.2. AstraZeneca plc.
• 31.3. Abbott Laboratories
• 31.4. Sanofi SA
• 31.5. GlaxoSmithKline plc
• 31.6. Takeda Pharmaceutical Company Limited
• 31.7. Johnson and Johnson Private Limited
• 31.8. Baxter International Inc.
• 31.9. Grifols S.A
• 31.10. Sun Pharmaceutical Industries Ltd.
• 31.11. Dr. Reddy's Laboratories Ltd.
• 31.12. Alembic Pharmaceuticals Limited
• 31.13. Lupin Pharmaceuticals Inc.
• 31.14. CSL Limited
• 31.15. Glenmark Pharmaceuticals Ltd.

32. Global Kernicterus Treatment Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Kernicterus Treatment Market

34. Recent Developments In The Kernicterus Treatment Market

35. Kernicterus Treatment Market High Potential Countries, Segments and Strategies

• 35.1 Kernicterus Treatment Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Kernicterus Treatment Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Kernicterus Treatment Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer